| Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial BA Wilky, MM Trucco, TK Subhawong, V Florou, W Park, D Kwon, ... The lancet oncology 20 (6), 837-848, 2019 | 272 | 2019 |
| Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution V Florou, AE Rosenberg, E Wieder, KV Komanduri, D Kolonias, ... Journal for immunotherapy of cancer 7, 1-8, 2019 | 139 | 2019 |
| Current and future directions for angiosarcoma therapy V Florou, BA Wilky Current treatment options in oncology 19, 1-13, 2018 | 90 | 2018 |
| Considerations for treatment duration in responders to immune checkpoint inhibitors TU Marron, AE Ryan, SM Reddy, S Kaczanowska, RH Younis, D Thakkar, ... Journal for immunotherapy of cancer 9 (3), 2021 | 65 | 2021 |
| Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort AR Naqash, B Ricciuti, DH Owen, V Florou, Y Toi, C Cherry, M Hafiz, ... Cancer Immunology, Immunotherapy 69, 1177-1187, 2020 | 65 | 2020 |
| Clinical and immunological implications of frameshift mutations in lung cancer YK Chae, P Viveiros, G Lopes, B Sukhadia, MM Sheikh, D Saravia, ... Journal of Thoracic Oncology 14 (10), 1807-1817, 2019 | 28 | 2019 |
| Therapeutic strategies for pigmented purpuric dermatoses: a systematic literature review KM Plachouri, V Florou, S Georgiou Journal of Dermatological Treatment 30 (2), 105-109, 2019 | 23 | 2019 |
| Models for mature T-cell lymphomas—a critical appraisal of experimental systems and their contribution to current T-cell tumorigenic concepts K Warner, G Crispatzu, N Al-Ghaili, N Weit, V Florou, MJ You, S Newrzela, ... Critical Reviews in Oncology/Hematology 88 (3), 680-695, 2013 | 19 | 2013 |
| Current management of angiosarcoma: recent advances and lessons from the past V Florou, BA Wilky Current Treatment Options in Oncology 22 (7), 61, 2021 | 16 | 2021 |
| Clinical activity of selitrectinib in a patient with mammary analogue secretory carcinoma of the parotid gland with secondary resistance to entrectinib V Florou, C Nevala-Plagemann, J Whisenant, P Maeda, GW Gilcrease, ... Journal of the National Comprehensive Cancer Network 19 (5), 478-482, 2021 | 16 | 2021 |
| Clinical development of anti-TIGIT antibodies for immunotherapy of cancer V Florou, I Garrido-Laguna Current Oncology Reports 24 (9), 1107-1112, 2022 | 14 | 2022 |
| Precision medicine in gastrointestinal stromal tumors V Florou, JC Trent, BA Wilky Discovery medicine 28 (155), 267-276, 2019 | 14 | 2019 |
| A phase II trial of axitinib plus pembrolizumab for patients with advanced alveolar soft part sarcoma (ASPS) and other soft tissue sarcomas (STS). BA Wilky, MM Trucco, D Kolonias, E Wieder, T Subhawong, A Rosenberg, ... Journal of clinical oncology 36 (15_suppl), 11547-11547, 2018 | 12 | 2018 |
| Global health perspective in sarcomas and other rare cancers V Florou, AG Nascimento, A Gulia, G de Lima Lopes Jr American Society of Clinical Oncology Educational Book 38, 916-924, 2018 | 10 | 2018 |
| The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors A Mittra, N Takebe, V Florou, AP Chen, AR Naqash Human Vaccines & Immunotherapeutics 17 (7), 1935-1939, 2021 | 9 | 2021 |
| P1. 07-025 correlating ISEND and tumor mutation burden (TMB) with clinical outcomes of advanced non-small cell lung cancer (ANSCLC) patients on nivolumab W Park, G Lopes, D Kwon, V Florou, YK Chae, J Warsch, A Ishkanian, ... Journal of Thoracic Oncology 12 (11), S2005-S2006, 2017 | 7 | 2017 |
| Latest advances in adult gastrointestinal stromal tumors V Florou, BA Wilky, JC Trent Future Oncology 13 (24), 2183-2193, 2017 | 7 | 2017 |
| Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction V Florou, S Puri, I Garrido-Laguna, BA Wilky Annals of Translational Medicine 9 (12), 2021 | 6 | 2021 |
| A precision medicine approach in sarcoma: identification of patients who may benefit from early use of pazopanib N Alavi, V Florou, G Tinoco, JC Trent, BA Wilky Discovery medicine 25 (137), 131-144, 2018 | 6 | 2018 |
| UPDATED DOSE ESCALATION RESULTS FOR REFOCUS, A FIRST-IN-HUMAN STUDY OF HIGHLY SELECTIVE FGFR2 INHIBITOR, RLY-4008, IN CHOLANGIOCARCINOMA AND OTHER SOLID TUMORS MJ Borad, AM Schram, RD Kim, SD Kamath, V Sahai, E Dotan, RK Kelley, ... Journal of Clinical Oncology 41 (16_suppl), 4009-4009, 2023 | 5 | 2023 |
